Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report

May 18, 2026 02:21 PM EDT PharmaFDA+Marketing Am­gen stands by Tavneos, de­spite re­ports of 20 deaths in Japan Andrew Dunn Senior Biopharma Correspondent The FDA wants it off the mar­ket. Eu­ro­pean reg­u­la­tors are in­ves­ti­gat­ing da­ta-in­tegri­ty con­cerns. And now, a phar­ma com­pa­ny sell­ing the drug in Japan is warn­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER